Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGFBPL1-targeted T cell engager
- Development stage
- Preclinical
- Lead developer
- MyriO Tx
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The IGFBPL1-targeted T cell engager is a bispecific antibody therapy being developed by Myrio Therapeutics (MyrioTx) for the treatment of small cell lung cancer (SCLC) and other neuroendocrine-phenotype malignancies. Utilizing the company's Retained Display (ReD) technology, the therapy consists of fully human single-chain variable fragments (scFvs) that specifically recognize a peptide derived from insulin-like growth factor binding protein-like 1 (IGFBPL1) presented by the HLA-A*02:01 molecule. IGFBPL1 is highly expressed in SCLC but silenced in healthy adult tissues, making it a selective target. The drug functions by simultaneously binding the IGFBPL1/HLA complex on cancer cells and the CD3 receptor on T cells, thereby inducing T cell-mediated cytotoxicity. It is currently in preclinical development, with IND-enabling studies underway.
- Other names
- IGFBPL1/HLA-A*02:01 bispecific T cell engagerIGFBPL1 x CD3 bispecific antibodyIGFBPL-1 x CD3 bispecific antibodyIGFBPL 1 x CD3 bispecific antibody
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on IGFBPL1-targeted T cell engager.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IGFBPL1-targeted T cell engager.